Health
Roche Bets Up to $1 Billion to Solve Gene Therapy’s Big Problem
The treatment has the potential to cure diseases, but high costs and a difficult delivery process have held it back.
Roche Holding AG, headquartered in Basel, Switzerland, aims to improve the delivery of gene therapies to patients.
Photographer: Pascal Mora/BloombergThis article is for subscribers only.
Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery.
The Swiss drugmaker has reached a new deal with Dyno Therapeutics Inc., a biotech focused on helping companies ensure that their gene therapies hit their intended targets, the companies said Thursday.